Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Robert Somerville"'
Autor:
John R. Wunderlich, Daniel J. Stephens, Liqiang Xi, Biman C. Paria, Smita S. Chandran, Arvind Sabesan, Mark Raffeld, Parthav Jailwala, Manjula Kasoji, Robert Somerville, Chyi-Chia Richard Lee, Trinh Hoc Tran Pham, Luke D. Rothermel, Abhishek K. Srivastava, Udai S. Kammula
Publikováno v:
Clinical Cancer Research. 22:2237-2249
Purpose: Uveal melanoma is a rare melanoma variant with no effective therapies once metastases develop. Although durable cancer regression can be achieved in metastatic cutaneous melanoma with immunotherapies that augment naturally existing antitumor
Autor:
Udai S. Kammula, Steven A. Rosenberg, Robert Somerville, John R. Wunderlich, Abhishek K. Srivastava, Daniel J. Stephens, Biman C. Paria, Smita S. Chandran, Mark E. Dudley, Luke D. Rothermel, Richard M. Sherry, James Chih-Hsin Yang
Publikováno v:
Clinical Cancer Research. 21:534-543
Purpose: Adoptive transfer of autologous tumor infiltrating lymphocytes (TIL) can mediate durable cancer regression in selected patients with metastatic melanoma. However, the tumor antigens associated with these favorable responses remain unclear. W
Autor:
Lori McIntyre, Jonathan W. Friedberg, Mark Roschewski, Udai S. Kammula, Stephanie L. Goff, Christopher A. Klebanoff, Richard M. Sherry, Robert Somerville, James N. Kochenderfer, Adrian Bot, Steven A. Feldman, Marika Sherman, Tatyana Feldman, Victoria Shi, Steven A. Rosenberg, Tangying Lu, Arianne Perez, John J. Rossi, Mary Ann Toomey, James Chih-Hsin Yang, Constance M. Yuan, Allen Xue
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 35(16)
Purpose T cells genetically modified to express chimeric antigen receptors (CARs) targeting CD19 (CAR-19) have potent activity against acute lymphoblastic leukemia, but fewer results supporting treatment of lymphoma with CAR-19 T cells have been publ
Autor:
Kathleen E. Morton, Udai S. Kammula, David N. Danforth, Thomas E. Shelton, Sadia Ilyas, Richard M. Sherry, Mary Ann Toomey, Eden C. Payabyab, Donald E. White, Seth M. Steinberg, Nicholas P. Restifo, Christopher A. Klebanoff, Michael S. Hughes, Steven A. Rosenberg, Mark E. Dudley, Deborah Citrin, Lily Lu, Nicholas D. Klemen, Mei Li M. Kwong, Daniel Zlott, James Chih-Hsin Yang, Michelle M. Langhan, John R. Wunderlich, Robert Somerville, Stephanie L. Goff
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 34(20)
Purpose Adoptive cell transfer, the infusion of large numbers of activated autologous lymphocytes, can mediate objective tumor regression in a majority of patients with metastatic melanoma (52 of 93; 56%). Addition and intensification of total body i
Autor:
Steven A. Rosenberg, Victoria Shi, Tangying L. Lu, Roger Kurlander, R. E. Gress, Brenna G. Hansen, Dennis D. Hickstein, Jeremy J. Rose, Steven A. Feldman, Jennifer N. Brudno, David Halverson, Bazetta Blacklock-Schuver, Irina Maric, Jennifer S. Wilder, Daniel H. Fowler, Robert Somerville, Juan C. Gea-Banacloche, Frances T. Hakim, Steven Z. Pavletic, James N. Kochenderfer, Andre Goy, Alexander T. Iwamoto
Purpose Progressive malignancy is the leading cause of death after allogeneic hematopoietic stem-cell transplantation (alloHSCT). After alloHSCT, B-cell malignancies often are treated with unmanipulated donor lymphocyte infusions (DLIs) from the tran
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78731f1c73af0683f0b5eca4e5d2e804
https://europepmc.org/articles/PMC4872017/
https://europepmc.org/articles/PMC4872017/
Autor:
Nicholas P. Schaub, James Chih-Hsin Yang, Richard M. Sherry, Udai S. Kammula, Robert Somerville, Nicholas P. Restifo, Steven A. Rosenberg, Seth M. Steinberg, Donald E. White, Debbie Ann N. Nathan, Colin A. Gross, Carolyn M. Laurencot, Giao Q. Phan, Rosati Shannon Faith, Young Hong, Michael S. Hughes, Mark E. Dudley, John R. Wunderlich
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 31(17)
Purpose Adoptive cell therapy (ACT) with autologous tumor-infiltrating lymphocytes (TILs) and high-dose interleukin-2 (IL-2) administered to lymphodepleted patients with melanoma can cause durable tumor regressions. The optimal TIL product for ACT is